Holen Sie sich die Stockscreener-App
85.23
4.06%
-3.605
Vorhandelsmarkt:
85.40
0.165
+0.19%
Monopar Therapeutics Inc Aktie (MNPR) Neueste Nachrichten
(MNPR) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Monopar Therapeutics stock price prediction: Support pressure looms at $81.33 - Traders Union
Form 144 MONOPAR THERAPEUTICS INC. For: 25 September By Investing.com - Investing.com Nigeria
Stock-option shares are proposed for sale by Chandler Robinson at Monopar Therapeutics (NASDAQ: MNPR). - Stock Titan
Monopar Therapeutics stock falls 7.5 percent on September 23 - AD HOC NEWS
Monopar Therapeutics shares drop more than 7% after stock trades below short-term moving averages - Traders Union
Why is Monopar Therapeutics stock down today? Key support levels to watch - Traders Union
Monopar Therapeutics stock trades on a clinical pipeline catalyst - AD HOC NEWS
H.C. Wainwright Maintains Monopar Therapeutics(MNPR.US) With Buy Rating, Maintains Target Price $125 - Moomoo
Monopar Therapeutics Inc (1IY0.MU) Analyst insights, Price targets and RecommendationsYahoo Finance - Yahoo Finance Singapore
Monopar Therapeutics stock trades quietly as investors weigh recent trial and funding updates - AD HOC NEWS
Monopar Therapeutics Inc.(NasdaqCM:MNPR) added to S&P Biotechnology Select Industry Index - marketscreener.com
MNPR slides nearly 5% as technical indicators confirm continued short-term weakness - Traders Union
Monopar Therapeutics stock trades near $92.46 support amid ongoing pullback - Traders Union
Monopar Therapeutics stock forecast: Selloff remains in focus - Traders Union
Monopar Therapeutics Is Maintained at Overweight by Barclays - Moomoo
MNPR Maintained by Barclays -- Price Target Raised to $145 - GuruFocus
Barclays Maintains Monopar Therapeutics(MNPR.US) With Buy Rating, Raises Target Price to $145 - Moomoo
Discipline and Rules-Based Execution in MNPR Response - Stock Traders Daily
Monopar Therapeutics shares technical analysis: $120.21 resistance in focus after rally - Traders Union
Monopar Therapeutics stock trades near record levels as investors react to insider selling and stron - AD HOC NEWS
What's behind Monopar Therapeutics's latest 3.0% stock pullback? - Traders Union
MNPR Q2 2026 Earnings: Narrower-Than-Expected Loss of $0.62 Highlights Clinical-Stage DisciplineEPS Miss Report - dars.gov.et
Monopar Therapeutics director Kim Tsuchimoto sells $455,566 in shares By Investing.com - Investing.com Canada
Monopar Therapeutics (MNPR) director sells 4,090 shares after option exercises - Stock Titan
Monopar Therapeutics director Raymond Anderson sells $351,835 in stock By Investing.com - Investing.com Canada
Monopar (MNPR) insider sells at $110–113 after $30 option exercise - Stock Titan
Will Monopar Therapeutics stock regain momentum as oversold conditions limit further selling? - Traders Union
Monopar director Kim Tsuchimoto sells $455k in common stock By Investing.com - Investing.com Nigeria
Monopar Therapeutics director Raymond Anderson sells $351k in stock By Investing.com - Investing.com Canada
Monopar Therapeutics Director Kim R. Tsuchimoto Executes Six-Tranche Stock Sale Under Rule 10b5-1 Plan - Kalkine Media
Monopar Therapeutics (MNPR) CMO uses plan to exercise options - Stock Titan
Monopar Therapeutics director Raymond Anderson sells USD 349,125 of common shares - Bitget
Monopar Therapeutics (MNPR) director sells 3,142 shares in plan trade - Stock Titan
Monopar Therapeutics (MNPR) director plans $906K share sale - Stock Titan
Monopar Therapeutics stock resistance test: Key levels to watch - tradersunion.com
Monopar (NASDAQ: MNPR) director to sell 6,284 shares - Stock Titan
Companies Like Monopar Therapeutics (NASDAQ:MNPR) Can Afford To Invest In Growth - webull.com
Monopar (MNPR) Quarter in Focus: EPS Clears the Reported Estimate in the Current Update; Trading Response: Shares Close 2.85% Lower in the Latest SessionForward EPS Estimate - vinanet.vn
Monopar (MNPR) Latest: Ends Lower by 2.85% at $107.72 in the Latest Reading; Technical Setup: Price Remains Between $102.33 Support and $113.11 Resistance at the CloseBreak of Structure - vinanet.vn
MNPR drops as short-term selling pressure persists - Traders Union
Morgan Stanley Maintains Monopar Therapeutics(MNPR.US) With Buy Rating, Raises Target Price to $130 - Moomoo
What's behind Monopar Therapeutics's latest stock pullback? - Traders Union
Monopar (MNPR) Chart: Retreats 2.41% to $120.85 in the Latest Reading; Price Levels: $114.81 and $126.89 Define the Nearby Reference Levels under the Current SnapshotLeveraged ETF Flow - vinanet.vn
Monopar (MNPR) Earnings Report: EPS Beats Its Estimate for the Current Session; Session Move: The Stock Ends Up 4.02% in the Latest ReadingInterim Report - vinanet.vn
Monopar appoints medical affairs head, presents at liver meeting By Investing.com - Investing.com South Africa
Monopar appoints medical affairs head, presents at liver meeting - Investing.com
Monopar Appoints Jeffrey D. Kent, M.D., as Executive Vice President, Head of Medical Affairs; Announces Two ALXN1840 Presentations at AASLDThe Liver Meeting® 2026 - The Manila Times
Monopar (MNPR) Price Update: Rises 1.94% to $118.75 at the Close; Price Context: the $112.81 to $124.69 Range Remains in Focus in the Latest ReadingLate Stage Breakouts - vinanet.vn
Monopar (MNPR) Close in Focus: Ends Up by 0.70% at $117.30 for the Current Session; Technical Position - vinanet.vn
Monopar: Licensing Agreement, Rolling NDA Submission Serve As Catalysts For ‘Strong Buy’ - Seeking Alpha
(MNPR) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Monopar Therapeutics (NASDAQ:MNPR) Cut to Sell at Wall Street Zen - MarketBeat
Zacks Research Downgrades Monopar Therapeutics (NASDAQ:MNPR) to Hold - MarketBeat
Equities Analysts Offer Predictions for MNPR FY2029 Earnings - MarketBeat
Buy Rating Reiterated on Monopar as ALXN-1840 Advances in Wilson Disease; $125 Price Target Maintained - TipRanks
Monopar Therapeutics Shares Drop After Downgrade From Cantor Fitzgerald - marketscreener.com
Monopar downgraded to Neutral at Cantor (MNPR:NASDAQ) - Seeking Alpha
This Stubhub Analyst Turns Bearish; Here Are Top 5 Downgrades For Thursday - Benzinga
MNPR Maintained by Barclays -- Price Target Raised to $128.00 - GuruFocus
MNPR Downgraded by Cantor Fitzgerald -- Price Target Raised to $119 - GuruFocus
Monopar Therapeutics Releases Q2 2026 Financial Results - AlphaStreet
Cantor downgrades Monopar stock on valuation after 90% rally - Investing.com
3.06%
2.55%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):